Value Investments for Your Stock Portfolio

Tag: Advanced Medical Solutions

H.B. Fuller FUL illustration showing eight directors buying $1.12M in shares, specialty adhesives production and 21% adjusted EPS growth.

H.B. Fuller ($FUL): 8 Directors Buy $1.12M in Stock—What Do They Know? 🧪💰

Eight H.B. Fuller ($FUL) directors have purchased approximately $1.12 million in stock near $50, following an earlier $295,000 purchase by CEO Celeste Mastin. Meanwhile, adjusted EPS jumped 21%, EBITDA margins reached a record 19.9%, and the stock trades at a forward P/E near 10×. Is this overlooked specialty adhesives manufacturer a compelling value opportunity—or a value trap? Our FunStock Index™: 8.0/10. 🧪📈

Read entire article

Tags: Adhesives Industry, Advanced Medical Solutions, BlackRock, buy or sell FUL, Capital Allocation, Celeste Mastin, Deleveraging, Director Stock Purchases, Dividend Stocks, Earnings Growth, EBITDA Margin, EBITDAMargins, featured-insiders, featured-value, Forward P/E, FUL, FUL Stock, FUL Stock Analysis, FUNanc1al, FunStock Index, FunStock Methodology, FunStockIndex, H.B. Fuller, H.B. Fuller Stock, HBFuller, hub-insiders, hub-value, Industrial Adhesives, Insider Buying, Insider Cluster Buying, InsiderBuying, Institutional Ownership, Medical Adhesives, R. Jeffrey Bailly, risks buying FUL, Specialty Chemicals, SpecialtyChemicals, Stock Market, Undervalued Stocks, Value Investing, ValueInvesting, why buy FUL